The dramatic advances-and controversies-of the past 25 years in understanding the epidemiology and treatment (both pharmacotherapy and psychotherapy), and the health care and delivery issues surrounding major depression are presented in this new book.
This highly readable volume stands out in the literature for two reasons: the high caliber of the contributors, internationally renowned experts from the United States, Switzerland, and the United Kingdom, and the diversity of topics, including the controversial role of the pharmaceutical industry in legitimizing depression as a medical illness as a means of creating markets for their products, the inherent conflict in treating depression under managed health care guidelines, the promise of genetics and basic and clinical biological sciences for developing new treatments, the contributions of the neurosciences and psychobiology, and the challenges ahead in ensuring that psychotherapy remains a reimbursable health care treatment. The volume concludes with a fascinating epilogue that highlights the paradox of over- and underuse of psychotherapy for depression, noting that very few of the more than 200 identified therapies have ever been tested and calling for new testing of psychotherapy in comparison or combination with pharmacotherapy.
At once wide-ranging and concise, this volume offers updates on both the medications and the psychotherapies used to treat depression worldwide. As such, it will appeal to a broad audience of psychiatrists, psychologists, social workers, and primary care practitioners.
|Hardcover Book, 384 pages||English|
|American Psychiatric Publishing, Inc. (Feb. 1st, 2001)||Unknown|
|9780880483971||6.38 x 9.06 x 1.08 inches|